As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Trinity Biotech plc. The largest reported stake is MiCo IVD Holdings, LLC's, at 17%. 8 filings are on record since October 24, 2025 (Schedule 13D/A, December 10, 2025).
Sell to companies like Trinity Biotech plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Perceptive Advisors LLC · Percent: 9.9% · SCHEDULE 13D/A
- · Holder: Novus Diagnostics Ltd. · Percent: 5.99% · SCHEDULE 13G
- · Holder: Perceptive Advisors LLC · Percent: 9.9% · SCHEDULE 13D/A
- · Holder: Perceptive Advisors LLC · Percent: 9.9% · SCHEDULE 13D/A
- · Holder: DAYLI Partners, Inc. · Percent: 0% · SCHEDULE 13D/A
Trinity Biotech plc has 8 Schedule 13D or 13G filings on record since 2025-10-24. 3 holders' latest filing reports 5% or more of class a ordinary shares, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| MiCo IVD Holdings, LLC | 17% | 69,450,720 | SCHEDULE 13D/A, 2025-12-10 | 2025-12-08 |
| Perceptive Advisors LLC | 9.9% | 3,424,019,957 | SCHEDULE 13D/A, 2026-05-04 | 2026-04-30 |
| Novus Diagnostics Ltd. | 5.99% | 1,119,988 | SCHEDULE 13G, 2026-03-06 | 2025-12-23 |
| DAYLI Partners, Inc. | 0% | 0 | SCHEDULE 13D/A, 2025-12-15 | 2025-12-02 |
Holding shares or following this stake? See who's behind Trinity Biotech plc and the warning signs.
Free to see. No signup.
Keep reading
More on Trinity Biotech plc and the records around it.
Trinity Biotech plc elsewhere on the record
Companies that share a holder
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)
Watch Trinity Biotech plc
Get an email when Trinity Biotech plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Trinity Biotech plc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Trinity Biotech plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Trinity Biotech plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Perceptive Advisors LLC
Item 4 of the Schedule 13D is hereby amended to add the following: On April 30, 2026, Credit Fund III, the Issuer and the other Issuer Credit Agreement Parties entered into that certain Limited Waiver and Third Amendment to the Sixth Amended and Restated Credit Agreement (the "Third Amendment"), which, among other things, provided for (i) a limited waiver by Credit Fund III of the Borrower's non-compliance with certain financial covenants contained in the Credit Agreement and (ii) an additional $2.5 million term loan borrowing. In connection with the Third Amendment, the Convertible Note was amended and restated (the "Amended and Restated Note") to increase the aggregate amount of indebtedness thereunder that is convertible into ADSs of the Issuer from US$60,000,000 to US$72,500,000 (as so amended, the "Conversion Cap"), and to reduce the minimum price at which indebtedness under the Convertible Note is convertible into ADSs from $1.03 per ADS to $0.5061 per ADS (as so amended, the "Floor Price"). On April 30, 2026, Credit Fund II, the Issuer and TRIB B entered into Amendment No. 1 to Conversion Rights Agreement (the "CRA Amendment"), pursuant to which the Conversion Rights Agreement was amended to reflect the above-described increase of the Conversion Cap and reduction of the Floor Price. The foregoing descriptions of the Third Amendment, the Amended and Restated Note and the CRA Amendment are not complete and, in each case, are qualified in their entirety by reference …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-04; the filing has the rest
DAYLI Partners, Inc.
Item 4 of the Original Schedule 13D is hereby amended by inserting the following new paragraph to the end: On December 2, 2025, DAYLI Holdings and AI n M completed the 2025 MiCo IVD Purchase, following which time the DAYLI Filers have no equity interest in MiCo IVD and do not, directly or indirectly, have any equity interest in the Issuer.Item 4 of the SCHEDULE 13D/A filed 2025-12-15
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-24 | Perceptive Advisors LLC | 22.5% | SCHEDULE 13D/A |
| 2025-12-04 | MiCo IVD Holdings, LLC | 17% | SCHEDULE 13D/A |
| 2025-12-10 | MiCo IVD Holdings, LLC | 17% | SCHEDULE 13D/A |
| 2025-12-15 | DAYLI Partners, Inc. | 0% | SCHEDULE 13D/A |
| 2025-12-23 | Perceptive Advisors LLC | 9.9% | SCHEDULE 13D/A |
| 2026-01-26 | Perceptive Advisors LLC | 9.9% | SCHEDULE 13D/A |
| 2026-03-06 | Novus Diagnostics Ltd. | 5.99% | SCHEDULE 13G |
| 2026-05-04 | Perceptive Advisors LLC | 9.9% | SCHEDULE 13D/A |
Questions about who owns Trinity Biotech plc
Who owns Trinity Biotech plc?
On this page, 3 holders' latest ownership filings report 5% or more of Trinity Biotech plc: MiCo IVD Holdings, LLC (17%, Schedule 13D/A, filed 2025-12-10), Perceptive Advisors LLC (9.9%, Schedule 13D/A, filed 2026-05-04) and Novus Diagnostics Ltd. (5.99%, Schedule 13G, filed 2026-03-06).
Who are the largest shareholders of Trinity Biotech plc?
By the share each holder's latest filing reports, the largest holders of Trinity Biotech plc on this page are MiCo IVD Holdings, LLC (17%), Perceptive Advisors LLC (9.9%) and Novus Diagnostics Ltd. (5.99%).
When did MiCo IVD Holdings, LLC buy into Trinity Biotech plc?
The filings give report dates, not purchase dates. The earliest filing from MiCo IVD Holdings, LLC on this page is the Schedule 13D/A, filed 2025-12-04, reporting 17%; its latest, Schedule 13D/A filed 2025-12-10, reports 17%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Trinity Biotech plc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.